Ultragenyx Pharmaceutical (RARE) Profit After Tax Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 33.04% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.60% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -154.28% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.53% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 47.10% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -4.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.10% |
| Dec 31, 2025 | 5.40% |
| Sep 30, 2025 | 9.71% |
| Jun 30, 2025 | 10.09% |
| Mar 31, 2025 | 0.29% |
| Dec 31, 2024 | -2.84% |
| Sep 30, 2024 | -22.29% |
| Jun 30, 2024 | -2.44% |
| Mar 31, 2024 | -7.83% |
| Dec 31, 2023 | -72.64% |
| Sep 30, 2023 | -32.36% |
| Jun 30, 2023 | -102.58% |
| Mar 31, 2023 | -11.27% |
| Dec 31, 2022 | -17.41% |
| Sep 30, 2022 | -29.45% |
| Jun 30, 2022 | -16.83% |
| Mar 31, 2022 | -16.33% |
| Dec 31, 2021 | -11.72% |
| Sep 30, 2021 | 5.79% |
| Jun 30, 2021 | -32.42% |
| Mar 31, 2021 | -86.63% |
| Dec 31, 2020 | -73.26% |
| Sep 30, 2020 | 4.57% |
| Jun 30, 2020 | 32.90% |
| Mar 31, 2020 | -20.34% |
| Dec 31, 2019 | -9.58% |
| Sep 30, 2019 | -20.30% |
| Jun 30, 2019 | -20.33% |
| Mar 31, 2019 | -22.41% |
| Dec 31, 2018 | -16.73% |
| Sep 30, 2018 | -30.56% |
| Jun 30, 2018 | -20.97% |
| Mar 31, 2018 | 50.59% |
| Dec 31, 2017 | 34.77% |
| Sep 30, 2017 | -70.98% |
| Jun 30, 2017 | -75.07% |
| Mar 31, 2017 | -71.11% |
| Dec 31, 2016 | -84.68% |
| Sep 30, 2016 | -97.48% |
| Jun 30, 2016 | -87.83% |
| Mar 31, 2016 | -98.60% |